Sumitomo pharm licenses out development rights to 2 S.Korean firms

摘要

Sumitomo Pharmaceuticals licensed, in late April, "Dops," an anti-Parkinson's disease agent, to Cheil Jhedang (South Korea), and "Rullan", an anti-schizophrenia agent, to Myung-In (South Korea). Under the agreement, each of the Korean firms may have the clinical development and sales rights for the agents for a 5-year period, and Sumitomo would supply them which formulated products.